was decreased to 18 °C. Afterwards, expression of UAXS was performed overnight in a Certomat BS-1 incubator (Sartorius Stedim).
Cells were harvested by centrifugation at 5000 rpm and 4 °C using a Sorvall Evolution RC centrifuge (Thermo Fisher Scientific, Waltham, Massachusetts, USA) equipped with a F10-S rotor and the pellet was stored at -20 °C. For purification, the cells were disrupted by a French Pressure Cell Press (American Instrument Company, Silver Spring, Maryland, USA) and solid parts were removed by centrifugation (16000 g, 4 °C, 60 min) on an Eppendorf 5415 R centrifuge (Eppendorf). The supernatant was filtered through a 1.2 µm Minisart filter (Sartorius Stedim) and loaded on a self-packed Cu 2+ -loaded IMAC sepharose column (GE Healthcare) using a BioLogic DuoFlow liquid chromatograph (Bio-Rad, Vienna, Austria). Elution was done using 50 mM Tris/HCl pH 7.5 buffers containing 5% (v/v) glycerol (buffer A and B) and 400 mM imidazole (buffer B). UAXS started eluting at 120 mM imidazole. All enzymecontaining fractions were pooled and the buffer was exchanged to 50 mM Tris/HCl pH 7.5 containing 5% (v/v) glycerol and 1 mM dithiothreitol using Amicon Ultra-15 centrifugal concentrators (Millipore, Vienna, Austria). Enzyme preparations were stored at -70 °C. The purity of the enzyme was checked with SDS-PAGE (NuPAGE 4-12% Bis-Tris-Gel, Life Technologies, Vienna, Austria) and Silver Staining ( Figure S1 ). UAXS concentrations were determined by UV spectroscopy (λ = 280 nm) on a DeNovix DS-11+ microvolume spectrophotometer (DeNovix) using a molar extinction coefficient ϵ of 48360 M -1 cm -1 and a molecular mass of 44703 Da (calculated by the ExPASy ProtParam web service).
Synthesis of UDP-α-D-glucuronic acid (3)
The synthesis is shown schematically in Scheme S1. The method for enzymatic synthesis of UDP-α-Dglucose was adapted from literature. 5, 6 The reaction mixture (3 mL) contained 15 mM (isotope-labeled) monosaccharide (8.11 mg, 0.045 mmol), 40-50 mM uridine 5'-triphosphate (UTP; 58.1-72.6 mg, 0.120-0.150 mmol), 5 mM MgCl 2 (1.43 mg, 0.015 mmol), 10 µM α-D-glucose 1,6-bisphosphate and 0.13% (w/v) bovine serum albumin (BSA; 3.9 mg) dissolved in 50 mM Tris/HCl buffer (pH 7.5). 12 U mL -1 hexokinase (36 U), 6 U mL -1 phosphoglucomutase (18 U), 1.2 U mL -1 UTP-glucose-1-phosphate uridylyltransferase (UGPase; 3.6 U) and 1.2 U mL -1 inorganic pyrophosphatase (PPase; 3.6 U) were added and the reaction was incubated at 30 °C for 24 hrs ( Figure S2 ). Upon completion, the mixture was split in three 1-mL-batches and synthesis of compound 3 was started by increasing temperature to 37 °C and adding 2 mM NAD + (1.33 mg, 0.002 mmol), 25 µM 9,10-phenanthrenequinone, 20 mM hydrogen peroxide (H 2 O 2 ; 0.68 mg, 0.020 mmol), 2.4 U mL -1 xylose reductase (CtXR; 2.4 U), 100 U mL -1 catalase (100 U) and 0.9 U mL -1 UDP-glucose dehydrogenase (hUGDH; 0.9 U) to each batch. The mixtures were incubated for 180 min and H 2 O 2 was fed in regular intervals, as described previously ( Figure S3 ). 7 Prior to chromatographic purification of 3, enzymes were removed by ultrafiltration using Vivaspin-6
centrifugal concentrators (Sartorius Stedim, Vienna, Austria). Purification of the produced nucleotide sugars was done using an ÄKTA FPLC liquid chromatograph (GE Healthcare, Vienna, Austria)
equipped with a 5 mL HiTrap Q HP (GE Healthcare) anion exchange column and a 2 mL sample loop. A step-wise gradient of 7.5 mL min -1 sodium chloride (buffer A: 20 mM and buffer B: 500 mM) in a 20 mM sodium acetate buffer (pH 4.2) was used for elution of bound compounds ( Figure S4 ). The steps were as follows: 6 mL NaCl 0 mM, 36.5 mL NaCl 75 mM, 26 mL NaCl 125 mM, 15 mL NaCl 500 mM, 15 mL NaCl 0 mM. Prior to each run, the column was regenerated flushing it with at least three column volumes of buffer B and buffer A. UV absorption (λ = 254 nm) was used to detect the target compounds, which were collected. All product-containing fractions were pooled and concentrated on a Laborota 4000 rotary evaporator (Heidolph, Schwabach, Germany) at 45 °C and 20 mbar to a final volume of approximately 4 mL.
NaCl was removed from nucleotide sugar preparations using ÄKTA FPLC with a 2 mL sample loop and a Superdex Peptide 10/300 GL size exclusion column (GE Healthcare). Elution was performed with deionized water at a flow rate of 1 mL min -1 . The target compound was detected by UV absorption (λ = 254 nm, Figure S5 ). Product-containing fractions were collected, pooled and concentrated on the Labo- 
Synthesis of UDP-2-deoxy-α-D-glucuronic acid (2-deoxy-3)
The synthesis is schematically shown in Scheme S2. 1,5-Anhydro-2-deoxy-D-arabino-hex-1-enitol was converted to 2-deoxy-α-D-glucose 1-phosphate by cellobiose phosphorylase (CuCPase) using a modification of the method published by Wildberger et al. 3 , and further on to UDP-2-deoxy-α-D-glucose by UGPase, as described for synthesis of substrate 3. The reaction mixture (3 × 1 mL) contained 40 mM glycal substrate (17.5 mg, 0.120 mmol), 20 mM UTP (29.1 mg, 0.060 mmol), 5 mM MgCl 2 (1.43 mg, 0.015 mmol) and 0.13% (w/v) BSA (3.9 mg) dissolved in 31 mM potassium phosphate buffer (pH 7.0).
After addition of 0.5 U mL -1 inorganic PPase (1.5 U), 84.5 U mL -1 UGPase (253.5 U) and 15 µM CuCPase (0.045 µmol), the reaction was incubated at 30 °C for 70 hrs. For synthesis of substrate analogue 2-deoxy-3, the pH was set to 7.5 and temperature was increased to 37 °C. After addition of 2 mM NAD + (1.33 mg, 0.002 mmol), 25 µM 9,10-phenanthrenequinone, 20 mM H 2 O 2 (0.68 mg, 0.020 mmol),
2.64 U mL -1 CtXR (2.64 U), 100 U mL -1 catalase (100 U) and 1.8 U mL -1 hUGDH (1.8 U) to each batch, the mixtures were incubated for 5.5 hrs. H 2 O 2 was fed in regular intervals as described previously. 7 A synthesis time course is shown in Figure S12 .
Purification was done according to substrate 3, however, a 1 mL SuperQ 650M column (Tosoh Bioscience GmbH, Stuttgart, Germany), a flow rate of 3 mL min -1 and the following steps were used: 16 mL NaCl 0 mM, 92 mL NaCl 20 mM, 20 mL NaCl 150 mM, 17 mL NaCl 500 mM, 16 mL NaCl mM ( Figure   S13 ). NaCl was separated from compound 2-deoxy-3 as described for substrate 3 ( Figure S14 ). Water was always removed under N 2 flow due to the instability of 2-deoxy-3. NMR and HPLC data are shown in Figures S15 -S18.
UAXS enzymatic reactions and assays
Reactions were performed at 30 °C on a Thermomixer Comfort (Eppendorf, Hamburg, Germany) without agitation. The reaction volume was typically 500 µL. If not stated otherwise, 2.0 mM of substrate were used. The buffer was 50 mM potassium phosphate, pH 8.5. In the case that D 2 O was used, the pD was set as pH meter reading plus 0.4. Purified UAXS (20 µM) was added to start the reaction and a sample was drawn immediately. Further samples were taken in regular intervals. For stopping the reaction, samples were heated to 99 °C for 5 min or mixed with acetonitrile (1:1 ratio). The samples were analyzed by HPLC as described below. Concentrations of substrate stock solutions were always confirmed by UV spectroscopy (λ = 262 nm) on a DeNovix DS-11+ microvolume spectrophotometer (DeNovix, Wilmington, Delaware, USA) using a molar extinction coefficient ε of 10 mM -1 cm -1 , as described in literature. 8 For measuring the pH profile of the activity of UAXS, the phosphate buffer was used in the pH range 6.0 -8.5, 50 mM sodium citrate was used between pH 5.0 and 6.0, and 50 mM Tris/HCl was used between pH 8.5 and 9.5. Reactions were performed identically as described above.
In the case of using UDP-2-deoxy-GlcA as the substrate of UAXS, alkaline phosphatase was added to the reaction (10 U mL -1 ) to convert any UDP present into uridine and phosphate. The UDP originates from spontaneous degradation of the unstable substrate, and it inhibits the enzyme.
High performance liquid chromatography
Samples were analyzed on a Shimadzu Prominence HPLC system (Shimadzu, Korneuburg, Austria) equipped with a 5 µm Kinetex C18 analytical HPLC column (4.6 × 50 mm; Phenomenex, Aschaffenburg, Germany) and a UV detector (λ = 262 nm). Precipitated protein was removed from samples by centrifugation (16000 g, 4 °C, 5 min) on an Eppendorf 5415 R centrifuge (Eppendorf), and after proper dilution, samples were measured using an injection volume of 5 µL, a temperature of 35 °C and a flow rate of 2 mL min -1 . Isocratic elution was performed using 87.5% 40 mM tetra-n-butylammonium bromide in 20 mM potassium phosphate buffer (pH 5.9) and 12.5% acetonitrile. Analysis time was 3.5 min (without UTP) or 4.5 min (with UTP). Authentic standards were used for calibration.
KIEs from intermolecular competition experiments: reactions and sample preparation
Reaction conditions were the same as for standard enzymatic assays, except that approximately 1 mM unlabeled substrate 3 and approximately 1 mM 3-2 H or 4-2 H substrate 3 were mixed to yield the final 6 substrate concentration. After the reaction had proceeded to the desired level (10 -70% conversion), enzymes were removed by ultrafiltration, as described for synthesis of substrate 3. Purification of the remaining substrate or the reaction products was done using an ÄKTA FPLC liquid chromatograph (GE Healthcare) equipped with a 5 mL HiTrap Q HP anion exchange column (GE Healthcare) and a 2 mL sample loop ( Figure S19 ). A step gradient of 7.5 mL min -1 ammonium formate buffer (buffer A: 20 mM and buffer B: 500 mM; pH 4.2) was used for elution of bound compounds ( Figure S4 ). Collected 5-mLfractions were lyophilized and subjected to desalting on a Superdex Peptide 10/300 GL column (GE Healthcare), as described above. After lyophilization and dissolution in D 2 O, all fractions were analyzed by NMR-spectroscopy. The isolation procedure was also applied to unreacted substrate and shown not introduce an isotope effect.
NMR spectroscopy (including in-situ analysis of enzymatic reactions) 9 A Varian (Agilent) INOVA 500-MHz NMR spectrometer (Agilent Technologies, Santa Clara, California, USA) and the VNMRJ 2.2D software were used for all measurements. 1 H NMR spectra (499.98 MHz) were measured on a 5 mm indirect detection PFG-probe, while a 5 mm dual direct detection probe with z-gradients was used for 13 C NMR spectra (125.71 MHz). NMR data were recorded from purified substances or reaction mixtures. In addition, they were also recorded from enzymatic in situ reactions performed at 30 °C in a total volume of 500 µL potassium phosphate buffer (50 mM; pD 8.5) in D 2 O containing 2 mM of the respective substrate and 20 -100 µM UAXS. 1 H NMR spectra were recorded with pre-saturation of the water signal by a shaped pulse in case of in situ experiments. Standard pre-saturation sequence was used: relaxation delay 2 s; 90° proton pulse; 2.048 s acquisition time;
spectral width 8 kHz; number of points 32 k. 13 C NMR spectra during in situ experiments were recorded with the following pulse sequence: standard 13 C pulse sequence with 45° carbon pulse, relaxation delay 2 s, Waltz decoupling during acquisition, 2 s acquisition time. Up to 256 scans were accumulated in one measurement. Arrayed spectra were acquired with an array of pre-acquisition delay of 30 min or 60 min.
HSQC spectra were measured with 128 scans per increment and adiabatic carbon 180° pulses. HETCOR spectra were recorded with 4 scans per increment and 256 increments. For KIE analysis, a standard proton experiment with relaxation delay of 25 s was used to record 1 H NMR spectra. ACD/NMR Processor Academic Edition 12.0 (Advanced Chemistry Development Inc.) was used for evaluation of spectra.
KIEs from intermolecular competition experiments: NMR analysis and KIE determination
Evaluation of the spectra for determination of the 1 H/ 2 H ratio was done using ACD/Processor Academic Edition NMR Processor Academic Edition 12.0 (Advanced Chemistry Development Inc., Toronto, Canada). Peaks were fitted with a Gauss+Lorentz function and optimized using a Levenberg-Marquadt algorithm, yielding peak areas. By comparison of the area of the isotopically replaced atom with the unaf-fected atoms, the 1 H/ 2 H ratio was determined. The total concentration of substrate (UDP-GlcA) or product (UDP-Xyl; UDP-Api measured as UMP) was measured by HPLC and converted to the individual concentrations of 1 H and 2 H substrate using the ratio determined by NMR spectroscopy. KIEs were then calculated for each point applying the formula KIE = ln(1 -F 1 )/ln(1 -F 2 ) (measuring the residual substrate). F 1 and F 2 correspond to the fractional conversions of the 1 H and 2 H substrate, respectively. The KIE determined thus is on the catalytic efficiency (V max /K m ).
KIEs from direct comparison of reaction rates
Enzymatic reactions were performed under the conditions described above (50 mM potassium phosphate buffer, pH 8. and time used. The KIE was calculated as the ratio of the V with unlabeled and deuterium-labeled substrate. The effect of substrate deuteration on the ratio of products formed from 3 was also analyzed.
Transient formation of enzyme-bound NADH
The UAXS as isolated contains tightly bound NAD + . Judging from absorbance at 340 nm in the purified protein, the enzyme does not contain NADH. External NAD + was not necessary for activity and addition The average value of the KIE is 2.47 ± 0.43. The average value of the KIE is 1.20 ± 0.03. The measurement at full conversion of 3 serves as a control. The initial isotope Ratio 3-2 H/3-1 H in substrate 3 was 0.736 (see Table S4 ).
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Supporting schemes
Scheme S1: The principle of enzymatic synthesis of substrate 3 and isotopically labeled analogues thereof is shown. UGPase, Bifidobacterium longum UTP-glucose-1-phosphate uridylyltransferase; inorganic PPase, pyrophosphatase; hUGDH, human UDP-glucose dehydrogenase; CtXR, Candida tenuis xylose reductase.
Scheme S2:
The principle of enzymatic synthesis of substrate analogue 2-deoxy-3 is shown. CuCPase, Cellulomonas uda cellobiose phosphorylase; UGPase, Bifidobacterium longum UTP-glucose-1-phosphate uridylyltransferase; inorganic PPase, pyrophosphatase; hUGDH, human UDP-glucose dehydrogenase; CtXR, Candida tenuis xylose reductase. Figure S1 . A SDS polyacrylamide gel of purified UAXS from A. thaliana (44.7 kDa) is shown. The gel also shows a molecular mass standard (masses in kDa) and the purified human UXS (38.6 kDa) that was also used in the current study. Figure S4 . Purification of substrate 3 (indicated by black box) using anion exchange chromatography (blue: UV signal, red: conductivity signal) is shown. Figure S5 . Removal of salt from substrate 3 by size exclusion chromatography is shown. Substrate 3 (indicated by black box) could be separated from NaCl in one step (blue: UV signal, red: conductivity signal). . A representative purification of compounds from the UAXS reaction mixture used for product characterization and for evaluation of intermolecular competition experiments (blue: UV signal, brown: conductivity signal, green: concentration buffer B) is shown. Product 8 elutes in peak/fraction 4 together with UMP, product 7 elutes in peak/fraction 6, and substrate 3 elutes in peak/fraction 9-10. GenBank AAGAGAATCCCAGACATGACCATCATTAACCGCCAACTCGGATGGAACCCGAAAACATCG 1077 Synthetic_gene AAACGTATTCCGGACATGACCATTATCAACCGCCAACTGGGTTGGAATCCGAAAACGAGC 1080 ** * ** ** *********** ** *********** ** ***** ******** GenBank CTATGGGACTTGCTCGAGTCGACCTTAACCTACCAGCACAGGACATACGCTGAAGCTGTG 1137 Synthetic_gene CTGTGGGATCTGCTGGAATCTACCCTGACGTATCAACATCGCACCTATGCCGAAGCAGTG 1140 ** ***** **** ** ** *** * ** ** ** ** * ** ** ** ***** *** GenBank AAGAAGGCAACATCCAAACCAGTGGCTTCCTAA---1170 Synthetic_gene AAAAAAGCTACCAGCAAACCGGTCGCAAGCCTCGAG 1176 ** ** ** ** ****** ** ** * Figure S29 . Sequence comparison of original AXS1 gene from GenBank and codon-optimized synthetic AXS1 gene used for recombinant UAXS production.
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ATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCAAATGGTGCGAACCGTGTGGACC 60 ******************************* Synthetic_gene TGGACGGCAAACCGATTCAACCGCTGACGATCTGTATGATTGGTGCTGGCGGCTTTATTG 91 Sequenced_gene TGGACGGCAAACCGATTCAACCGCTGACGATCTGTATGATTGGTGCTGGCGGCTTTATTG 120 ************************************************************ Synthetic_gene GTAGTCATCTGTGCGAAAAACTGCTGACCGAAACGCCGCACAAAGTTCTGGCCCTGGATG 151 Sequenced_gene GTAGTCATCTGTGCGAAAAACTGCTGACCGAAACGCCGCACAAAGTTCTGGCCCTGGATG 180 ************************************************************ Synthetic_gene TCTATAACGACAAAATCAAACATCTGCTGGAACCGGATACCGTTGAATGGAGCGGCCGTA 211 Sequenced_gene TCTATAACGACAAAATCAAACATCTGCTGGAACCGGATACCGTTGAATGGAGCGGCCGTA 240 ************************************************************ Synthetic_gene TTCAGTTTCATCGCATTAACATCAAACACGATTCTCGCCTGGAAGGTCTGGTCAAAATGG 271 Sequenced_gene TTCAGTTTCATCGCATTAACATCAAACACGATTCTCGCCTGGAAGGTCTGGTCAAAATGG 300 ************************************************************ Synthetic_gene CAGACCTGATTATCAATCTGGCGGCCATTTGTACGCCGGCTGATTATAACACCCGTCCGC 331 Sequenced_gene CAGACCTGATTATCAATCTGGCGGCCATTTGTACGCCGGCTGATTATAACACCCGTCCGC 360 ************************************************************ Synthetic_gene TGGACACGATCTACAGTAATTTCATTGATGCACTGCCGGTGGTTAAATACTGCAGTGAAA 391 Sequenced_gene TGGACACGATCTACAGTAATTTCATTGATGCACTGCCGGTGGTTAAATACTGCAGTGAAA 420 ************************************************************ Synthetic_gene ACAACAAACGCCTGATCCATTTTTCCACCTGTGAAGTGTACGGCAAAACGATTGGTTCCT 451 Sequenced_gene ACAACAAACGCCTGATCCATTTTTCCACCTGTGAAGTGTACGGCAAAACGATTGGTTCCT 480 ************************************************************ Synthetic_gene TCCTGCCGAAAGATCACCCGCTGCGTGATGACCCGGCTTTTTATGTTCTGAAAGAAGACA 511 Sequenced_gene TCCTGCCGAAAGATCACCCGCTGCGTGATGACCCGGCTTTTTATGTTCTGAAAGAAGACA 540 ************************************************************ Synthetic_gene TTAGTCCGTGCATCTTCGGCTCCATTGAAAAACAGCGTTGGTCTTATGCATGTGCTAAAC 571 Sequenced_gene TTAGTCCGTGCATCTTCGGCTCCATTGAAAAACAGCGTTGGTCTTATGCATGTGCTAAAC 600 ************************************************************ Synthetic_gene AACTGATTGAACGCCTGGTCTACGCGGAAGGCGCCGAAAACGGTCTGGAATTTACCATCG 631 Sequenced_gene AACTGATTGAACGCCTGGTCTACGCGGAAGGCGCCGAAAACGGTCTGGAATTTACCATCG 660 ************************************************************ Synthetic_gene TGCGTCCGTTCAATTGGATTGGCCCGCGCATGGATTTTATTCCGGGCATCGACGGTCCGT 691 Sequenced_gene TGCGTCCGTTCAATTGGATTGGCCCGCGCATGGATTTTATTCCGGGCATCGACGGTCCGT 720 ************************************************************ Synthetic_gene CAGAAGGTGTGCCGCGCGTTCTGGCGTGCTTCTCGAACAATCTGCTGCGTCGCGAACCGC 751 Sequenced_gene CAGAAGGTGTGCCGCGCGTTCTGGCGTGCTTCTCGAACAATCTGCTGCGTCGCGAACCGC 780 ************************************************************ Synthetic_gene TGAAACTGGTGGATGGCGGTGAAAGCCAGCGTACCTTTGTGTATATCAATGACGCAATTG 811 Sequenced_gene TGAAACTGGTGGATGGCGGTGAAAGCCAGCGTACCTTTGTGTATATCAATGACGCAATTG 840 ************************************************************ Synthetic_gene AAGCTGTTCTGCTGATGATCGAAAACCCGGAACGTGCGAATGGCCACATTTTCAACGTTG 871 Sequenced_gene AAGCTGTTCTGCTGATGATCGAAAACCCGGAACGTGCGAATGGCCACATTTTCAACGTTG 900 ************************************************************ Synthetic_gene GTAATCCGAACAATGAAGTCACCGTGCGCCAACTGGCCGAAATGATGACGGAAGTCTACG 931 Sequenced_gene GTAATCCGAACAATGAAGTCACCGTGCGCCAACTGGCCGAAATGATGACGGAAGTCTACG 960 ************************************************************ Synthetic_gene CGAAAGTGTCAGGCGAAGGTGCCATCGAATCGCCGACCGTTGATGTCAGCTCTAAAGAAT 991 Sequenced_gene CGAAAGTGTCAGGCGAAGGTGCCATCGAATCGCCGACCGTTGATGTCAGCTCTAAAGAAT 1020 ************************************************************ Synthetic_gene TTTATGGCGAAGGTTACGATGACAGCGATAAACGTATTCCGGACATGACCATTATCAACC 1051 Sequenced_gene TTTATGGCGAAGGTTACGATGACAGCGATAAACGTATTCCGGACATGACCATTATCAACC 1080 ************************************************************ Synthetic_gene GCCAACTGGGTTGGAATCCGAAAACGAGCCTGTGGGATCTGCTGGAATCTACCCTGACGT 1111 Sequenced_gene GCCAACTGGGTTGGAATCCGAAAACGAGCCTGTGGGATCTGCTGGAATCTACCCTGACGT 1140 ************************************************************ Synthetic_gene ATCAACATCGCACCTATGCCGAAGCAGTGAAAAAAGCTACCAGCAAACCGGTCGCAAGCC 1171 Sequenced_gene ATCAACATCGCACCTATGCCGAAGCAGTGAAAAAAGCTACCAGCAAACCGGTCGCAAGCC 1200 ************************************************************ Synthetic_gene TCGAG------------------------------------------1176 Sequenced_gene TCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCC 1247 ***** Figure S30 . Sequence comparison of synthetic AXS1 gene as obtained by the supplier and sequencing results after plasmid isolation. The C-terminal His 6 tag is visible at the end of the sequenced gene.
